Cramp Bark

Viopudial, a sesquiterpene isolated from Viburnum opulus, has documented hypotensive activity (Nicholson et al., Proc Soc Exp Biol Med, 1972). It acts as a smooth muscle relaxant and peripheral vasodilator. Combined with antihypertensive medications, additive blood pressure lowering may cause symptomatic hypotension, dizziness, and syncope.

Monitor blood pressure when cramp bark is used alongside antihypertensive medications. Warn patients about potential dizziness or fainting. Consider reducing antihypertensive dose if blood pressure falls below target range. Discontinue cramp bark before surgical procedures requiring haemodynamic stability.

Cramp bark contains scopoletin and scopaline (coumarins), which have theoretical anticoagulant properties by inhibiting vitamin K-dependent clotting factor synthesis. It also contains salicylates and salicosides with mild antiplatelet activity. Although no clinical case reports have been published, the combined pharmacological profile warrants caution.

No well-documented clinical interactions have been identified. However, given the coumarin content, monitor INR in patients on warfarin who use cramp bark regularly. Advise patients on anticoagulants to disclose herbal use. Avoid cramp bark at supplemental doses in patients with bleeding disorders or on dual anticoagulant/antiplatelet therapy.

Cramp bark (Viburnum opulus) is a well-established smooth and skeletal muscle relaxant via scopoletin (spasmolytic coumarin) and viopudial (calcium-channel inhibition in smooth muscle). Combined with pharmaceutical muscle relaxants, additive antispasmodic and CNS-sedating effects may occur, potentially causing excessive muscle weakness, drowsiness, and impaired coordination.

Caution is warranted when cramp bark is used alongside prescription muscle relaxants. Monitor for signs of excessive muscle relaxation: weakness, poor coordination, difficulty ambulating. Particularly relevant in elderly patients. Inform anaesthetists of cramp bark use before surgery as it may prolong neuromuscular effects.

Cramp bark has documented uterine spasmolytic activity mediated by scopoletin and viopudial, which relax uterine smooth muscle via calcium antagonism. In obstetric settings, this could antagonise the uterotonic effects of oxytocin or prostaglandins used for labour induction or postpartum haemorrhage prevention, potentially compromising uterine tone and haemostasis.

Cramp bark should be discontinued before planned labour induction or in any obstetric situation requiring uterotonic support. Alert obstetric and midwifery teams if patients are using cramp bark. Do not use cramp bark concurrently with oxytocin or prostaglandins intended to maintain uterine contractility postpartum. Despite its traditional use for dysmenorrhoea, it is contraindicated in active labour management.

Viburnum opulus phenolic compounds have demonstrated inhibitory effects on carbohydrate hydrolases (alpha-glucosidase, pancreatic lipase) in vitro, which could additive lower post-prandial blood glucose. In studies on MIN6 insulinoma cells, Viburnum phenolics showed cytoprotective and glucose-modulatory effects relevant to diabetes.

The clinical significance at standard cramp bark doses is low. However, patients on antidiabetic medications who use cramp bark supplements should monitor blood glucose levels. Advise against high-dose supplementation without monitoring. Inform diabetes care teams of any herbal supplement use.

Both cramp bark (via salicylates and anti-inflammatory phenolics) and NSAIDs inhibit cyclooxygenase enzymes and prostaglandin synthesis. Combined use could lead to additive GI mucosal injury and renal prostaglandin suppression, especially with prolonged concurrent use. Additionally, cramp bark has traditional use for dysmenorrhoea, which overlaps with NSAID indications.

Cramp bark and NSAIDs both address dysmenorrhoea; combined use for menstrual cramps is common but should be monitored. GI protection (proton pump inhibitor) may be appropriate with prolonged concurrent use. Monitor renal function. Avoid in patients with peptic ulcer disease or renal impairment.